{"id":"isx-group","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL1222381","moleculeType":"Small molecule","molecularWeight":"234.28"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Unfortunately, there is limited information available on ISX Group's mechanism of action, making it difficult to provide a detailed explanation.","oneSentence":"ISX Group's mechanism of action is not publicly available.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:17:21.592Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT00244101","phase":"PHASE3","title":"Delivery Room Management Trial of Premature Infants at High Risk of Respiratory Distress Syndrome","status":"COMPLETED","sponsor":"Vermont Oxford Network","startDate":"2003-08","conditions":"Respiratory Distress Syndrome, Newborn","enrollment":648}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":10,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Intubation, Surfactant Administration, Extubation to Nasal CPAP. ENSURE."],"phase":"phase_3","status":"active","brandName":"ISX Group","genericName":"ISX Group","companyName":"Vermont Oxford Network","companyId":"vermont-oxford-network","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}